Avidity Biosciences Inc (RNA) Stock Price, Quote & News

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stag...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 401 7900

Website: www.aviditybiosciences.com

Address:

10578 Science Center Drive, Suite 125, San Diego, United States

wwmeinc Aug. 8 at 10:08 PM

$RNA ...Some vesting shares/options....exercised...nice gains...glta https://www.secform4.com/filings/1599901/0001599901-25-000157.htm

1 · Reply

wwmeinc Aug. 8 at 9:00 PM

$RNA ...Nice buy at the close...glta 16:09:03 Q $46.29 $-1.23 1,106,266 shrs

0 · Reply

MavisProuty1011 Aug. 8 at 4:53 PM

$RNA W K S P float dryin up, vol gunna slap

1 · Reply

JarvisFlow Aug. 8 at 3:27 PM

Wells Fargo has adjusted their stance on Avidity Biosciences ( $RNA ), setting the rating to Overweight with a target price of 70 → 75.

0 · Reply

MikeGabbert487 Aug. 8 at 3:11 PM

$RNA Guys, what I found about W-K-S-P 👀—chart coiling around $3.60 with volume drying up. Something's coming…

0 · Reply

wwmeinc Aug. 8 at 2:31 PM

$IOVA $RNA $GOSS ......This is quite an interesting article dated Aug.7/25....regarding the MRK/Verona deal...No other bidders appeared. The initial offer and Verona's counter-offer...gives some insight...albeit....not investment bank round-table but some insight...worth a read. Just an opinion. glta https://www.fiercepharma.com/pharma/its-10b-buyout-verona-merck-was-lone-ranger

0 · Reply

wwmeinc Aug. 8 at 2:06 PM

$RNA ...Lots of price upgrades....interest seems to be here...B/O or not...lots to like...just my opinion though...as the 'rumour' will either unfold this wknd or not...~$9B or so...and $10B would hit the jackpot ;)) glta https://www.biospace.com/drug-development/5-dmd-candidates-to-watch-in-2025

0 · Reply

thesharkinthedark Aug. 8 at 1:40 PM

$RNA

0 · Reply

JarvisFlow Aug. 8 at 12:30 PM

Chardan Capital has adjusted their stance on Avidity Biosciences ( $RNA ), setting the rating to Buy with a target price of 75.

0 · Reply

theoptionsplug Aug. 8 at 4:38 AM

Notable companies due to report earnings & their implied moves: 🤖Tempus AI $TEM ~10.42% 🍔Wendy's $WEN ~8.03% ⛽EOG Resources $EOG ~3.10% 🧬Avidity Biosciences $RNA ~13.47%

0 · Reply

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 11:41 AM EDT - 2 days ago

Novartis weighs deal for biotech Avidity Biosciences, FT reports

NVS

Jul 28, 2025, 9:00 AM EDT - 11 days ago

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

Jul 23, 2025, 9:00 AM EDT - 16 days ago

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping

Jun 11, 2025, 9:00 AM EDT - 2 months ago

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

Jun 9, 2025, 7:01 AM EDT - 2 months ago

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

Jun 9, 2025, 7:00 AM EDT - 2 months ago

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

May 21, 2025, 4:05 PM EDT - 2 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 4:05 PM EDT - 3 months ago

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights

May 6, 2025, 9:00 AM EDT - 3 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

Apr 8, 2025, 9:00 AM EDT - 4 months ago

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Mar 31, 2025, 9:00 AM EDT - 4 months ago

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Mar 17, 2025, 7:00 AM EDT - 5 months ago

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial

Mar 12, 2025, 4:05 PM EDT - 5 months ago

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 28, 2025, 9:00 AM EST - 5 months ago

Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases

Feb 27, 2025, 4:05 PM EST - 5 months ago

Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights

Feb 25, 2025, 9:00 AM EST - 5 months ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Jan 8, 2025, 9:00 AM EST - 7 months ago

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

Dec 11, 2024, 9:25 AM EST - 8 months ago

Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases

Nov 12, 2024, 7:00 AM EST - 9 months ago

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations

Nov 7, 2024, 4:05 PM EST - 9 months ago

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights

Oct 31, 2024, 9:00 AM EDT - 10 months ago

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

Sep 24, 2024, 2:15 PM EDT - 11 months ago

Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month

Aug 27, 2024, 9:30 AM EDT - 1 year ago

Life Science Cares San Diego Scales Partnership with Avidity Biosciences Through Life Science Shares Program

Aug 19, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Aug 16, 2024, 3:21 PM EDT - 1 year ago

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 14, 2024, 8:30 PM EDT - 1 year ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Aug 9, 2024, 4:05 PM EDT - 1 year ago

Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 5, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer

Jun 24, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

CTNM

Jun 20, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day

Jun 17, 2024, 4:05 PM EDT - 1 year ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 13, 2024, 8:00 PM EDT - 1 year ago

Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

Jun 12, 2024, 4:01 PM EDT - 1 year ago

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

Jun 12, 2024, 10:15 AM EDT - 1 year ago

Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday

CASY RTO

May 19, 2024, 11:23 AM EDT - 1 year ago

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

May 15, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors

May 9, 2024, 4:05 PM EDT - 1 year ago

Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Feb 29, 2024, 1:39 PM EST - 1 year ago

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29, 2024, 12:00 PM EST - 1 year ago

Avidity Biosciences Honors Rare Disease Day®

Feb 29, 2024, 7:00 AM EST - 1 year ago

Avidity Biosciences Announces Oversubscribed $400 Million Private Placement

Feb 28, 2024, 4:05 PM EST - 1 year ago

Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights

Jan 5, 2024, 8:30 AM EST - 1 year ago

Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth

Nov 28, 2023, 7:43 AM EST - 1 year ago

Avidity Stock Soars on Collaboration Deal With Bristol Myers

BMY

Nov 28, 2023, 6:46 AM EST - 1 year ago

Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

BMY

Nov 8, 2023, 4:05 PM EST - 1 year ago

Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights

Sep 26, 2023, 9:00 AM EDT - 2 years ago

Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society

Sep 7, 2023, 9:00 AM EDT - 2 years ago

Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs

wwmeinc Aug. 8 at 10:08 PM

$RNA ...Some vesting shares/options....exercised...nice gains...glta https://www.secform4.com/filings/1599901/0001599901-25-000157.htm

1 · Reply

wwmeinc Aug. 8 at 9:00 PM

$RNA ...Nice buy at the close...glta 16:09:03 Q $46.29 $-1.23 1,106,266 shrs

0 · Reply

MavisProuty1011 Aug. 8 at 4:53 PM

$RNA W K S P float dryin up, vol gunna slap

1 · Reply

JarvisFlow Aug. 8 at 3:27 PM

Wells Fargo has adjusted their stance on Avidity Biosciences ( $RNA ), setting the rating to Overweight with a target price of 70 → 75.

0 · Reply

MikeGabbert487 Aug. 8 at 3:11 PM

$RNA Guys, what I found about W-K-S-P 👀—chart coiling around $3.60 with volume drying up. Something's coming…

0 · Reply

wwmeinc Aug. 8 at 2:31 PM

0 · Reply

wwmeinc Aug. 8 at 2:06 PM

0 · Reply

thesharkinthedark Aug. 8 at 1:40 PM

$RNA

0 · Reply

JarvisFlow Aug. 8 at 12:30 PM

Chardan Capital has adjusted their stance on Avidity Biosciences ( $RNA ), setting the rating to Buy with a target price of 75.

0 · Reply

theoptionsplug Aug. 8 at 4:38 AM

Notable companies due to report earnings & their implied moves: 🤖Tempus AI $TEM ~10.42% 🍔Wendy's $WEN ~8.03% ⛽EOG Resources $EOG ~3.10% 🧬Avidity Biosciences $RNA ~13.47%

0 · Reply

thesharkinthedark Aug. 7 at 9:19 PM

$RNA people say they shouldn’t accept any deal below 70$ Sounds pretty bullish $QQQ $SPY

0 · Reply

wwmeinc Aug. 7 at 7:34 PM

$RNA ....seems like a nice risk/reward scenario being set-up now that data is out...and 'chatter' abounds...sometimes you just got to believe in your instincts in these type of situations and of course be prepared to be disappointed if a B/O does not come around. Timelines can be very fluid....Here's to a nice pay-off though! Good trading and glta. https://whalewisdom.com/stock/rna

0 · Reply

RonIsWrong Aug. 7 at 7:07 PM

$RNA JANUS HENDERSON GROUP PLC added 670,475 shares on 7/31 (or 705,412 shares) Shared Voting Power is now: 12,132,108.00 Percent of class represented by amount in row (9) 10.1 %

1 · Reply

thesharkinthedark Aug. 7 at 12:10 PM

$RNA I’m SO BULLISH! 🧬🧑🏼‍⚕️👩🏼‍⚕️ 60$ soon? $SPY $QQQ $XBI $XLV

0 · Reply

Atomickb Aug. 7 at 11:12 AM

$RNA - its a travesty that pumper juanan showed up. Now its bad juju. Not one of his pumps have ever come true. The last 2 days he has been shooting random numbers 120 130 100. All he has is a random number generator

1 · Reply

juananthebest Aug. 7 at 11:08 AM

$RNA 100$

0 · Reply

juananthebest Aug. 7 at 11:08 AM

$RNA they will acquire it today

0 · Reply

Atomickb Aug. 7 at 9:53 AM

$RNA - Also has 11 $ per share in cash. So even if they get bougbt for 70 the actual cost woulf be 59 . Lets say 60 which is 7.2 billion tag. 5 billion is too low

0 · Reply

shopno Aug. 7 at 8:55 AM

BREAKING: $NVS looking to acquire $RNA -- now sitting at $5.8B with no revenue. They have two P3 including MD1, and one P2 DMD trials. Compare that to $SRPT at $1.6B valuation with $2B+ revenue. https://www.ft.com/content/0e2c4788-141c-4dcf-9da9-1c3c6ab9dde1

0 · Reply

SannieVerraderlijk Aug. 7 at 8:53 AM

$SRPT look at pre-revenue $RNA for a reasonable price target on SRPT

1 · Reply

JohnGadwin Aug. 7 at 7:05 AM

$RNA What's your price target? I say 70-80$ analysts says the same!

1 · Reply

JohnGadwin Aug. 7 at 7:00 AM

$RNA Volume don't lie... BIG MOVE and i guess its not the end

0 · Reply

Market Cap	5.73B
Revenue (ttm)	10.90M
Net Income (ttm)	-322.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,956.88%
Debt to Equity Ratio	0.00

Volume	4,929,300
Avg Vol	2,505,244
Day's Range	N/A - N/A
Shares Out	120.52M
Stochastic %K	86%
Beta	0.95
Analysts	Strong Sell
Price Target	$66.56